JBC Origene Your Gene Company

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Foster, P. A.
Right arrow Articles by Zimmerman, T. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Foster, P. A.
Right arrow Articles by Zimmerman, T. S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J. Biol. Chem., Vol. 262, Issue 18, 8443-8446, Jun, 1987

A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor

PA Foster, CA Fulcher, T Marti, K Titani and TS Zimmerman

We have identified a Factor VIII (FVIII) binding domain residing within the amino-terminal 272 amino acid residues of the mature von Willebrand Factor (vWF) subunit. Two-dimensional crossed immunoelectrophoresis showed direct binding of purified human FVIII to purified human vWF. After proteolytic digestion of vWF with Staphylococcus aureus V8 protease (SP), FVIII binding was seen only with the amino-terminal SP fragment III and not with the carboxyl-terminal SP fragment II. A monoclonal anti-vWF antibody (C3) partially blocked FVIII binding to vWF and SP fragment III. FVIII also bound to vWF which had been adsorbed to polystyrene beads. This binding was inhibited in a dose- dependent manner by whole vWF, SP fragment III, and by monoclonal antibody C3. Binding could not be inhibited by SP fragment I, which contains the middle portion of the vWF molecule, or by reduced and alkylated whole vWF. SP fragment II caused only minimal inhibition. Trypsin cleavage of SP fragment III produced a monomeric 35-kDa fragment containing the amino-terminal 272 amino acid residues of vWF. This fragment reacted with monoclonal antibody C3 and inhibited the binding of FVIII to vWF in a dose-dependent manner. These studies demonstrate that a major FVIII binding site resides within the amino- terminal 272 amino acid residues of vWF.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
B. W. Shen, P. C. Spiegel, C.-H. Chang, J.-W. Huh, J.-S. Lee, J. Kim, Y.-H. Kim, and B. L. Stoddard
The tertiary structure and domain organization of coagulation factor VIII
Blood, February 1, 2008; 111(3): 1240 - 1247.
[Abstract] [Full Text] [PDF]

Home page
 CLIN APPL THROMB HEMOSTHome page
A. Casonato, E. Pontara, F. Sartorello, M.G. Cattini, P. Perutelli, A. Bertomoro, L. Gallinaro, and A. Pagnan
Identifying Carriers of Type 2N von Willebrand Disease: Procedures and Significance
Clinical and Applied Thrombosis/Hemostasis, April 1, 2007; 13(2): 194 - 200.
[Abstract] [PDF]

Home page
 BloodHome page
G. Michaux, T. J. Pullen, S. L. Haberichter, and D. F. Cutler
P-selectin binds to the D'-D3 domains of von Willebrand factor in Weibel-Palade bodies
Blood, May 15, 2006; 107(10): 3922 - 3924.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. C. Spiegel, P. Murphy, and B. L. Stoddard
Surface-exposed Hemophilic Mutations across the Factor VIII C2 Domain Have Variable Effects on Stability and Binding Activities
J. Biol. Chem., December 17, 2004; 279(51): 53691 - 53698.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Casonato, F. Sartorello, M. G. Cattini, E. Pontara, C. Soldera, A. Bertomoro, and A. Girolami
An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant
Blood, January 1, 2003; 101(1): 151 - 156.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Jorieux, E. Fressinaud, J. Goudemand, C. Gaucher, D. Meyer, C. Mazurier, and the INSERM Network on Molecular Abnormalities in v
Conformational changes in the D' domain of von Willebrand factor induced by CYS 25 and CYS 95 mutations lead to factor VIII binding defect and multimeric impairment
Blood, May 15, 2000; 95(10): 3139 - 3145.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Allen, A. M. Abuzenadah, J. L. Blagg, J. Hinks, I. M. Nesbitt, A. C. Goodeve, T. Gursel, J. Ingerslev, I. R. Peake, and M. E. Daly
Two novel type 2N von Willebrand disease-causing mutations that result in defective factor VIII binding, multimerization, and secretion of von Willebrand factor
Blood, March 15, 2000; 95(6): 2000 - 2007.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. P. Schwarz, P. J. Lenting, B. Binder, J. Mihaly, C. Denis, F. Dorner, and P. L. Turecek
Involvement of low-density lipoprotein receptor-related protein (LRP) in the clearance of factor VIII in von Willebrand factor-deficient mice
Blood, March 1, 2000; 95(5): 1703 - 1708.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. V. Bendetowicz, R. J. Wise, and G. E. Gilbert
Collagen-bound von Willebrand Factor Has Reduced Affinity for Factor VIII
J. Biol. Chem., April 30, 1999; 274(18): 12300 - 12307.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Mazzucato, P. Spessotto, A. Masotti, L. De Appollonia, M. R. Cozzi, A. Yoshioka, R. Perris, A. Colombatti, and L. De Marco
Identification of Domains Responsible for von Willebrand Factor Type VI Collagen Interaction Mediating Platelet Adhesion under High Flow
J. Biol. Chem., January 29, 1999; 274(5): 3033 - 3041.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. J. Kaufman, A. J. Dorner, and D. N. Fass
von Willebrand Factor Elevates Plasma Factor VIII Without Induction of Factor VIII Messenger RNA in the Liver
Blood, January 1, 1999; 93(1): 193 - 197.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Jorieux, C. Gaucher, J. Goudemand, and C. Mazurier
A Novel Mutation in the D3 Domain of von Willebrand Factor Markedly Decreases Its Ability to Bind Factor VIII and Affects Its Multimerization
Blood, December 15, 1998; 92(12): 4663 - 4670.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. V. Bendetowicz, J. A. Morris, R. J. Wise, G. E. Gilbert, and R. J. Kaufman
Binding of Factor VIII to von Willebrand Factor Is Enabled by Cleavage of the von Willebrand Factor Propeptide and Enhanced by Formation of Disulfide-Linked Multimers
Blood, July 15, 1998; 92(2): 529 - 538.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Gu, S. Jorieux, J.M. Lavergne, C. Ruan, C. Mazurier, and D. Meyer
A Patient With Type 2N von Willebrand Disease Is Heterozygous for a New Mutation: Gly22Glu. Demonstration of a Defective Expression of the Second Allele by the Use of Monoclonal Antibodies
Blood, May 1, 1997; 89(9): 3263 - 3269.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Goto, D. R. Salomon, Y. Ikeda, and Z. M. Ruggeri
Characterization of the Unique Mechanism Mediating the Shear-dependent Binding of Soluble von Willebrand Factor to Platelets
J. Biol. Chem., October 6, 1995; 270(40): 23352 - 23361.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. L. Saenko and D. Scandella
A Mechanism for Inhibition of Factor VIII Binding to Phospholipid by von Willebrand Factor
J. Biol. Chem., June 9, 1995; 270(23): 13826 - 13833.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1987 by the American Society for Biochemistry and Molecular Biology.